News Releases
In this section
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 27, 2021
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its...
-
Jul 8, 2021
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
Jun 4, 2021
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
May 25, 2021
Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will...
-
May 19, 2021-Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from a total of nine...
-
May 13, 2021
Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced registered underwritten public offering (the "Equity Offering") of 11,500,000 shares of its common stock...
-
May 11, 2021
Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 10,000,000 shares of its common stock (the "Shares") at a price to the public of...
-
May 10, 2021
BRIDGEWATER, N.J., May 10, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell $250 million of its common stock (the "Shares") and $500...
-
May 7, 2021
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement...
-
May 6, 2021--ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first...
Contact Us
